摘要
目的基于微阵列数据研究G蛋白信号调节因子3(RGS3)与乳腺癌的预后关系,为乳腺癌的治疗提供潜在的靶点及预后参考因素。方法通过Kaplan-Meier Plotter平台(http://kmplot.com/analysis/)的微阵列数据库分析RGS3高/低表达对不同类型乳腺癌以及伴有高复发危险因素乳腺癌10年、15年生存的影响。结果根据10年、15年的随访数据,R GS3的高表达与基底样型乳腺癌的不良预后有关(P=0.032),并且与伴有高复发危险因素乳腺癌的不良预后密切相关,包括激素受体阴性(P=0.000)、HER-2过表达(P=0.004)、肿瘤组织学3级(P=0.009)、TP53阳性表达(P=0.046)和腋窝淋巴结转移阳性(P=0.005)等。结论 RGS34高表达与乳腺癌的恶性生物学特征有关,提示R GS3可以成为乳腺癌潜在的治疗靶点和有效的预后参考因素。
Objective Toexplore the relationship between Gprotein signalregulator 3(RGS3)and the prognosis ofbreast cancer,and to provide potential targets for the treatment of breast cancer and effective reference factors for the prognosis of breast cancer. Methods The effect of high/low expression of RGS3 on 10-year and 15-year survival of different types of breast cancer and breast cancer with high recurrence risk factors was analyzed by the microarray database of Kaplan-Meier Plotter(http://kmplot.com/analysis/).Results According to the follow-up data of 10-and 15-years,the high expression of RGS3 was related to the adverse prognosis of baseline-like breast cancer(P=0.032),and was closely related to the adverse prognosis of breast cancer with high recurrence risk factors,including the hormone receptor negative expression(P=0.000),the HER-2 over-expression(P=0.004),the histological grade 3(P=0.009),the TP53 positive expression(P=0.046),and the axillary lymph node metastasis(P=0.005). Conclusion The high expression of RGS3 is related to the malignant biological characteristics of breast cancer,suggesting that RGS3 may be a potential therapeutic target and an effective prognostic reference factor for breast cancer.
引文
[1]SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2017[J].CACancer J Clin,2017,67(1):7-30.
[2]BRAY F,FERLAY J,SOERIOMATARAM I,et al.Global Cancer Statistics 2018:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2018,68(6):394-424.
[3]LEHMANN B D,BAUER J A,CHEN X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J].J Clin Invest,2011,121(7):2750-2767.
[4]GERRATANA L,FANOTTO V,BONOTTO M,et al.Pattern of metastasis and outcome in patients with breast cancer[J].Clin Exp Metastasis,2015,32(2):125-133.
[5]DULIN N O,PRATT P,TIRUPPATHI C,et al.Regulator of G protein signaling RGS3T is localized to the nucleus and induces apoptosis[J].JBiol Chem,2000,275(28):21317-21323.
[6]EUSEMANN T N,WILLMROTH F,FIEBICH B,et al.Adenosine receptors differentially regulate the expression of regulators of G-protein signalling(RGS)2,3 and 4 in astrocyte-like cells[J].PLo S One,2015,10(8):e0134934.
[7]SETHAKORN N,DULIN N O.RGS expression in cancer:oncomining the cancer microarray data[J].J Recept Signal Transduct,2013,33(3):166-171.
[8]TATENHORST L,SENNER V,PUTTMANN S,et al.Regulators of Gprotein signaling 3 and 4(RGS3,RGS4)are associated with glioma cell motility[J].J Neuropathol Exp Neurol,2004,63(3):210-222.
[9]WANG J,ZHOU Y,FEI X,et al.Regulator of G-protein signaling 3targeted by mi R-126 correlates with poor prognosis in gastric cancer patients[J].Anticancer Drugs,2017,28(2):161-169.
[10]GYOFFY B,LANCZKY A,EKLUND A C,et al.An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients[J].Breast Cancer Res Treatment,2010,123(3):725-731.
[11]CHEN Z,WU Y,MENG Q,et al.Elevated micro RNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3[J].In Vitro Cell Dev Biol Anim,2016,52(1):62-67.